Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions encompass a wide range of insights, including skepticism about the mineral oil placebo's effects and the limited benefits of icosapent ethyl. Phrases such as 'mineral oil was harmful' and 'placebo manipulation' indicate an intensive examination of the methods and implications of the study. The tone varies from curiosity to critical analysis, reflecting deep engagement among participants.
While there are varying opinions, many discussions align with the findings about the effects of icosapent ethyl and mineral oil.
The topic generates significant curiosity, especially regarding the implications of the study for cardiovascular health.
Participants show deep engagement, examining the nuances of the research, methods, and situational context.
The discussions highlight a strong perception that the publication's findings could influence future research and clinical practices.
An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects on biomarkers assoc w/atherosclerotic disease, whereas levels increased among those allocated to mineral oil (the control). https://t.co/p9GVnyJL4W https://t.co/2x4R1yAz0I
Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
A
High dose EPA (Vascepa) MOA remains enigmatic - Is anything known that can explain the benefit of EPA in REDUCE IT? - Here is the trial's advanced biomarker study - https://t.co/gGo37X3eOI https://t.co/5BO4GFNiS2
1/2 An important paper was just published on biomarker study in REDUCE-IT (EPA vs mineral oil). It shows the mineral oil "placebo" group had significant increases in 7 biomarkers associated with higherCVD risk, incl Lp(a) (2.4%) and IL1-b (48%). https://t.co/9Ds3Dnnfm2
Response RE "Effects of Randomized Treatment with Icosapent Ethyl and a Mineral Oil Comparator on Interleukin" https://t.co/GS6noMPTzI @DLBHATTMD @Drlipid @lipiddoc @braun_lynne @gpokmd @skepcard @Lpa_Doc @BudoffMd @VietHeartPA @mmillermd1 @SABOURETCardio @drpablocorral
This week, John Mandrola MD discusses evolving perspectives on cardiovascular health. Highlighting the American Heart Association's updates to its health framework, the podcast emphasizes a proactive approach to health…
@sigal_alan Alan fíjate lo que produce el placebo del Reduce-IT sobre los marcadores inflamatorios Por otro lado IL-6 estimula la síntesis de apo(a) hepatica.
@FGProcopio @clarincom @florcunzolo No no Fabricio; ApoB es LDL + Lp(a) + LRT (lipoproteinas ricas en TG), todo en conjunto. Con respecto a los efectos del placebo del Reduce-It, los propios autores publicaron esto Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on
@fmfclips It may have been because the placebo (mineral oil in this case) was harmful, not that the EPA was beneficial. https://t.co/I31OSUlMyI https://t.co/JbsajeXIno
Please also read this substudy of REDUCE IT It puts the results of REDUCE IT in perspective. https://t.co/26kMnzOGja
@ValleAlfonso @ESC_Journals @SantasEnrique @preventiva_SEC @pegpao @siacprevent @JTLLERGO @Drroxmehran @vic_pallares @chemachir @rafavidalperez @DrMarthaGulati Para interpretar en su contexto https://t.co/uAQtg6GGW6
@DrK1985 Mineral oilがCRPを増やして悪さをしたからEPAがよくでたのではないかという理論です 著者らもそれを認めています https://t.co/BpWXUBsP7H
@theproof I agree narrowly with what you say, but the reduced clearance rate of LDL-C is captured by apoB, and TG are not themselves causal, so it remains unneccessary to target it as such except when v. severely elevated. Also,doing so w/omega-3 is of dubious value:https://t.co/cBGO38l0iq
@soonergise @SCC_CCS @CCPNRx @DLBHATTMD @Drlipid @PeterAttiaMD @VietHeartPA @Lpa_Doc @DeBakeyCVedu @khurramn1 @BudoffMd @PamTaubMD @nationallipid @lipo_fan @RichardAFerraro See: https://t.co/94rFqp4XXZ
@MarkBrady2014 @SCC_CCS @CCPNRx @DLBHATTMD @Drlipid @PeterAttiaMD @VietHeartPA @Lpa_Doc @DeBakeyCVedu @khurramn1 @BudoffMd @PamTaubMD @nationallipid @lipo_fan @RichardAFerraro I really want to believe in Vascepa. Or high dose EPA. Would love to here thoughts on this however, which takes it back to mineral oil as likely not being an inert placebo. https://t.co/rQ0xn66wSe
@neeche41 @DanClintonRN @nationallipid This analysis is interesting. Thoughts? https://t.co/rQ0xn66wSe
RT @fipco: A
@kevinnbass @DrCamRx @AbudBakri Study - ICO will not address other biomarkers related to CVD except Trigs. They’re saying ICO was oversold in relation to what it does. But, keeping Trigs to <100 and your Trig/HDL ratio to <2 ideally 1, are good indicators of metabolic and cardio health https://t.co/5wql7rOspY
@rene_maltais Are you aware about this manuscript of Dr Bhatt, Ridker, Steg, Tardif, Mason…? https://t.co/x7XQqzDvsD
RT @JRoon71: Response RE "Effects of Randomized Treatment with Icosapent Ethyl and a Mineral Oil Comparator on Interleukin" https://t.co/GS…
RT @JRoon71: Response RE "Effects of Randomized Treatment with Icosapent Ethyl and a Mineral Oil Comparator on Interleukin" https://t.co/GS…
RT @JRoon71: Response RE "Effects of Randomized Treatment with Icosapent Ethyl and a Mineral Oil Comparator on Interleukin" https://t.co/GS…
RT @JRoon71: Response RE "Effects of Randomized Treatment with Icosapent Ethyl and a Mineral Oil Comparator on Interleukin" https://t.co/GS…
RT @JRoon71: Response RE "Effects of Randomized Treatment with Icosapent Ethyl and a Mineral Oil Comparator on Interleukin" https://t.co/GS…
Response RE "Effects of Randomized Treatment with Icosapent Ethyl and a Mineral Oil Comparator on Interleukin" https://t.co/GS6noMPTzI @DLBHATTMD @Drlipid @lipiddoc @braun_lynne @gpokmd @skepcard @Lpa_Doc @BudoffMd @VietHeartPA @mmillermd1 @SABOURETCardio @drpablocorral
@GeoWizz_ Placebo: an inactive substance or other intervention that looks the same as, and is given the same way as, an active drug or treatment being tested Not these
RT @fipco: A
@GeoWizz_ Great speculation - but again where is the "Mounting Evidence" you cite where such actions correlate with RR reduction seen in REDUCE. ⬇️TG were not related. This biomarker analysis found nothing supportive: https://t.co/gGo37X3MEg
RT @fipco: A
Do you believe the CV benefit in REDUCE-IT was from icosapent ethyl or a detrimental effect of the mineral oil comparator? Icosapent ethyl had minimal effect on biomarkers but levels increased among those on mineral oil. #CardioTwitter #EndoTwitter https://t.co/P8FKL9r6FG
RT @BowTiedLoon: This paper more or less proves that the study that got icosapent ethyl (pharma grade purified EPA) only looked like it wor…
This paper more or less proves that the study that got icosapent ethyl (pharma grade purified EPA) only looked like it worked due to PLACEBO MANIPULATION. https://t.co/rcIekOvuOf
Eine aktuelle Neuauswertung der REDUCE-IT-Studie zeigt nun: Möglicherweise haben maßgebliche negativen Wirkungen des "Placebos" (Mineralöl) zu den vermeintlich positiven Effekten von #Vazkepa beigetragen. 5/x https://t.co/WHHVPOcCEW
For everyone interested in #omega3 this paper from #REDUCEIT published in @CircAHA by #PaulRidker/@DLBHATTMD is a must-read This comprehensive analysis of inflammatory/lipid biomarkers revealed minimal changes from #IPE & sign increases from #MineralOil https://t.co/VtsoslQUbX
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipa https://t.co/clHtogCgEt
RT @fipco: A
RT @fipco: A
RT @fipco: A
RT @fipco: A
RT @fipco: A
When a placebo is not a placebo https://t.co/nmWK6DPH5K via @CircAHA #cardiovascular #omega3s #MineralOil Which "Placebo effect?" (and why it matters) https://t.co/A507ZGhAxm https://t.co/psfJAMRY1f
REDUCE-IT posthoc analysis shows biomarkers associated with ASCVD were increased among those allocated to mineral oil. I feel like I'm very late to this party. @DaveDixonPharmD https://t.co/iGxIlE9pRc
3 yrs later, the authors publish a biomarker substudy suggesting the 'improvements' may in fact relate to a pro-inflammatory effect of the mineral oil placebo. Icosapent ethyl itself may be neutral at best. 2/... https://t.co/GL5fkW1ApR
In a nutshell, Amarin won exclusive FDA approval for fish oils as *drugs for treatment of cardiovascular disease*—prescribable by MDs & reimbursable by insurers—owing to statistical improvements over mineral oil, which we now know was *causing disease* https://t.co/QvWu5F72af
RT @pnatarajanmd: Wow- based on recent @CircAHA paper (https://t.co/6LZ5uWCYfp), 2 @US_FDA panelists would have reconsidered their support…
Wow- based on recent @CircAHA paper (https://t.co/6LZ5uWCYfp), 2 @US_FDA panelists would have reconsidered their support for Amarin’s Vascepa. Excellent article summarizing the issues https://t.co/JDyd85aPMC @statnews by @matthewherper https://t.co/SX5DvmbasS
RT @CircAHA: #OriginalResearch: In this substudy of the REDUCE-IT #RCT, atherosclerotic biomarkers did not change in the icosapent ethyl gr…
#OriginalResearch: In this substudy of the REDUCE-IT #RCT, atherosclerotic biomarkers did not change in the icosapent ethyl group but increased over time in the mineral oil comparator group @gabrielsteg @DLBhattMD @mmillermd1 #AHAJournals https://t.co/BogLIVQC6a https://t.co/m27llrPYT7
RT @vic_pallares: Effects of Randomized Treatment W/ Icosapent Ethyl & a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, CRP, Oxid…
RT @vic_pallares: Effects of Randomized Treatment W/ Icosapent Ethyl & a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, CRP, Oxid…
RT @vic_pallares: Effects of Randomized Treatment W/ Icosapent Ethyl & a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, CRP, Oxid…
RT @vic_pallares: Effects of Randomized Treatment W/ Icosapent Ethyl & a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, CRP, Oxid…
RT @Drlipid: High dose EPA (Vascepa) MOA remains enigmatic - Is anything known that can explain the benefit of EPA in REDUCE IT? - Here is…
RT @vic_pallares: Effects of Randomized Treatment W/ Icosapent Ethyl & a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, CRP, Oxid…
RT @vic_pallares: Effects of Randomized Treatment W/ Icosapent Ethyl & a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, CRP, Oxid…
Effects of Randomized Treatment W/ Icosapent Ethyl & a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, CRP, Oxidized LDL-c, Homocysteine, Lipoprotein(a), & Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy.
https://t.co/Uy3K24Vkbn More evidence to suggest that mineral oil (the OTC laxative distilled from crude oil) is NOT a benign placebo... Would be cool to see the same analysis repeated for the corn oil arm of the STRENGTH trial.
RT @fipco: A
RT @fipco: A
Effects of Rnd Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized LDL-C, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy https://t.co/KaZLGLtKxG
RT @fipco: A
RT @fipco: A
RT @fipco: A
RT @fipco: A
DOI isn't working right now, this link works https://t.co/rsZwJIGj6Q https://t.co/h0e85gGGhN
@TheBhupiThakur DOI isn't up yet lol, thanks for the heads up https://t.co/rsZwJIGj6Q
RT @fipco: A
A
RT @agingdoc1: Effects of [RCT] With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxi…
...A REDUCE-IT Biomarker Substudy (open access) https://t.co/cSQVGXG04y
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2...
Link to new biomarker secondary analysis: https://t.co/E2PDRfVEHg
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
"The effect of these findings on interpretation of the overall risk reductions in clinical events observed within REDUCE-IT is uncertain" From: REDUCE-IT Substudy
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
"Among participants in REDUCE-IT, allocation to icosapent ethyl had minimal effects on a series of biomarkers associated with atherosclerotic disease, whereas levels increased among those allocated to mineral oil." https://t.co/ajuJQ4HSwR
Effects of [RCT] With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a)...[a REDUCE-IT Substudy] https://t.co/ajuJQ4HSwR Bound to re-ignite controversy...
RT @Drlipid: High dose EPA (Vascepa) MOA remains enigmatic - Is anything known that can explain the benefit of EPA in REDUCE IT? - Here is…
RT @Drlipid: High dose EPA (Vascepa) MOA remains enigmatic - Is anything known that can explain the benefit of EPA in REDUCE IT? - Here is…
RT @danielisazamd: Más información ante las discusiones de EPA vs Mineral oil.
RT @Drlipid: High dose EPA (Vascepa) MOA remains enigmatic - Is anything known that can explain the benefit of EPA in REDUCE IT? - Here is…
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
High dose EPA (Vascepa) MOA remains enigmatic - Is anything known that can explain the benefit of EPA in REDUCE IT? - Here is the trial's advanced biomarker study - https://t.co/gGo37X3eOI https://t.co/5BO4GFNiS2
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
Más información ante las discusiones de EPA vs Mineral oil.
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
@holmanm https://t.co/xEaLoCEEax
RT @Lpa_Doc: 1/2 An important paper was just published on biomarker study in REDUCE-IT (EPA vs mineral oil). It shows the mineral oil "plac…
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
@DLBHATTMD can you pls comment on your Circulation article published yesterday? Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Etc.
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
https://t.co/vbLKoD7jbp
RT @Lpa_Doc: 1/2 An important paper was just published on biomarker study in REDUCE-IT (EPA vs mineral oil). It shows the mineral oil "plac…
1/2 An important paper was just published on biomarker study in REDUCE-IT (EPA vs mineral oil). It shows the mineral oil "placebo" group had significant increases in 7 biomarkers associated with higherCVD risk, incl Lp(a) (2.4%) and IL1-b (48%). https://t.co/9Ds3Dnnfm2
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
RT @hmkyale: An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects o…
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
An exceptionally imp article: 'data indicate that in REDUCE-IT, allocation to icosapent ethyl had minimal effects on biomarkers assoc w/atherosclerotic disease, whereas levels increased among those allocated to mineral oil (the control). https://t.co/p9GVnyJL4W https://t.co/2x4R1yAz0I
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
RT @venkmurthy: Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers:
Secondary analysis of REDUCE-IT trial of icosapent ethyl shows mineral oil placebo worsened many biomarkers: